Printed from Voxsanity (voxsanity.com.au) — NCT04019548 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Head And Neck Cancer
Phase 3 Head and Neck Cancer Trial, Recruiting
NCT04019548
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People of any gender
- People who have been newly diagnosed with a specific type of throat cancer (squamous cell carcinoma of the oropharynx), confirmed by a tissue sample (biopsy)
- People whose cancer has not spread to distant parts of the body and for whom doctors are planning treatment aimed at curing the cancer using radiation and drug therapy
- People who have not had any previous cancer treatment for this condition (such as chemotherapy or surgery)
- People who have biopsy results and HPV/p16 test results available
- People with a general health status that allows them to carry out basic daily activities (confirm with trial site)
- People whose bone marrow is working well enough, shown by blood test results meeting specific levels for white blood cells, red blood cells, and platelets
- People whose liver is functioning well enough, shown by blood test results within specific ranges
- People whose kidneys are functioning well enough, shown by specific blood and urine test results
- People with little or no nerve damage (peripheral neuropathy no worse than very mild)
- People with little or no hearing loss (no worse than very mild)
- Women who could become pregnant must have a negative pregnancy blood test within 7 days before starting treatment
- Women who could become pregnant must agree to use a highly effective form of contraception before, during, and for at least 6 months after treatment ends
- Men whose partners could become pregnant must agree to use a condom during the study and for at least 6 months after treatment ends
- People who are able to understand and complete questionnaires, as assessed by the lead doctor
- People who complete all required screening tests within 15 days before being enrolled in the trial
- People who have signed a consent form before any study-related procedures begin
Who may not be able to join:
- People who are severely malnourished
- People who have significant difficulty swallowing and require a liquid or pureed diet
- People whose cancer has spread to distant parts of the body
- People with serious blood clotting disorders
- People with significant uncontrolled medical, psychiatric, or surgical conditions that, in the lead doctor's opinion, could interfere with completing the study
- People who have had another cancer in the past 3 years (with some exceptions for certain early-stage or skin cancers — confirm with trial site)
- Women who are pregnant or breastfeeding
- People with a known allergy or sensitivity to cisplatin (the study drug) or its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Jules Bordet Institute
Registry
ClinicalTrials.gov
Start date
16 December 2019
Est. completion
1 November 2027
Where this trial is recruiting
🇧🇪 Belgium
Primary endpoints
global M.D. Anderson Dysphagia Inventory score at 6 months after end of treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.